Did you know that up to 50% of women diagnosed with breast cancer under age 45 are diagnosed within 10 years of childbirth?
Known as postpartum breast cancer, this is a highly more aggressive and often under-recognized form of the disease that affects ~18,000 new mothers each year.
In this HIE Impact story, a unique partnership between researcher and clinician is driving change.
Traci Lyons, PhD, and Ginger Borges, MD, are working together to understand why these cancers behave differently and how to stop them. Their discovery of a key biological driver (sema7a) has led to a potential first-in-class therapy, now being advanced through their startup, Pearl Scientific.
The therapy has already shown incredible promise in early-stage studies, not only slowing down the cancer progression but completely killing the cancer cells in mice.
Watch the story:
Through the new Healthcare Innovation & Entrepreneurship (HIE) Initiative, we’re expanding our legacy of innovation, empowering more faculty, clinicians, and students to turn bold ideas into patient impact: Sign Up!
